FDA’s New CDER Director Grants Approval of Yet Another Expensive, Scientifically Questionable Drug  ...  More Will Follow. The FDA’s Center for Drug Evaluation and Research (CDER) approval of aducanumab (Aduhelm) for Alzheimer’s is the latest in a series of decisions where the FDA appeared to bow to politics and public pressure rather than scientific findings.